{"brief_title": "Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes", "brief_summary": "The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.", "condition": "Diabetes Mellitus, Non-Insulin-Dependent", "intervention_type": "Drug", "intervention_name": "Ruboxistaurin mesylate", "criteria": "Inclusion Criteria: - Patients must have type I or type II Diabetes Mellitus. - Have clinically diagnosed positive sensory symptoms such as numbness, lancinating pain, burning pain, aching pain, allodynia and prickling sensation that have been present not greater than 5 years but stable for 6 months. - Has a HbA1C less than or equal to 12%. Patients with HbA1C greater than 9% must be on insulin therapy. - Must be 18 years or older. - Be able to visit the doctor's office approximately 3 times over a maximum of a 6-week period to determine if you can continue in the study. Exclusion Criteria: - History of significant liver problems. - Have poor kidney function. - Drink an excess of alcohol or abuse drugs. - Have recently participated or currently participating in a Medical study in which you receive an experimental drug. - Are a woman and are pregnant or breastfeeding, intend to become pregnant within the next 2 years or a woman not using effective birth control.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00044395.xml"}